Trades

Trade Date Price Time Type Volume
1 29-09-2021 65 15:35:18 d-H -100000
2 29-09-2021 65 13:09:28 dH 200000
3 29-09-2021 65 13:09:28 d-H -100000
4 30-09-2021 66.95 09:19:34 29871
5 30-09-2021 66.811 09:16:06 29926
6 30-09-2021 65.66 09:14:16 20000
7 30-09-2021 66.95 09:09:44 2407
8 30-09-2021 66.255 08:09:25 NTd 50000
9 30-09-2021 66.95 09:08:40 990

ohlcv

Close Date High Low Open Volume
63.000000 13-09-2021 63.000000 60.000000 61.500000 597063
60.000000 14-09-2021 62.400002 60.000000 62.000000 405350
59.500000 15-09-2021 60.500000 59.500000 60.000000 292852
60.000000 16-09-2021 60.500000 59.500000 59.500000 112316
61.000000 17-09-2021 61.000000 60.000000 60.000000 179927
57.500000 20-09-2021 61.000000 57.500000 61.000000 363959
57.000000 21-09-2021 58.000000 56.000000 57.500000 287504
58.000000 22-09-2021 59.500000 57.000000 57.000000 310307
57.000000 23-09-2021 58.500000 57.000000 58.000000 639773
60.000000 24-09-2021 60.000000 58.500000 58.500000 150098
63.000000 27-09-2021 63.000000 63.000000 60.000000 348073
64.800003 28-09-2021 64.800003 64.800003 63.000000 1765130

New research agreement initiated with the University of Manchester

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that it has initiated a research programme with the University of Manchester (“the University”) to investigate and develop microbiome formulations that support natural anti-inflammatory response to a range of environmental challenges. Expanding the collaboration with the University was one of the areas of investment laid out by the Company when it raised funds via placing and open offer in October 2020.

» Download full article

Expanded enrolment for AxisBiotix-PsTM food supplement consumer study

SkinBioTherapeutics plc

(“SkinBioTherapeutics” or “the Company”)

Expanded enrolment for AxisBiotix-PsTM food supplement consumer study

  • Study size increased to 250 from 200, following high demand for places
  • Study to commence by end February 2021
  • Participants’ feedback on AxisBiotix-PsTM to be monitored through smart devices

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that AxisBiotix Limited, a wholly owned subsidiary of the Company, has increased the size of its food supplement consumer study from 200 to 250 participants, following a high level of demand.

Read more